-       Report 
- October 2025
-  192 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  196 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  191 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
           -       Report 
- October 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- October 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- July 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- March 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Report 
- April 2025
-  80 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Report 
- January 2025
-  135 Pages 
- Global 
   From       €2280EUR$2,549USD£2,006GBP 
      €2682EUR$2,999USD£2,360GBP 
          -       Drug Pipelines 
- June 2025
-  200 Pages 
- Global 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Drug Pipelines 
- June 2025
-  200 Pages 
- Global 
   From       €2495EUR$2,789USD£2,194GBP 
       
      Fluorouracil (5-FU) is a chemotherapy drug used in the treatment of cancer. It is a pyrimidine analog, which interferes with the synthesis of DNA and RNA, leading to cell death. It is used to treat a variety of cancers, including breast, colorectal, gastric, pancreatic, and head and neck cancers. It is also used in combination with other drugs to treat advanced or metastatic cancers. Fluorouracil is administered intravenously or topically, depending on the type of cancer being treated.
Fluorouracil    is a widely used drug in the oncology market, and is often used in combination with other drugs to treat advanced or metastatic cancers. It is a generic drug, and is available in both branded and generic formulations. The branded formulations are typically more expensive than the generic versions.
Companies in the Fluorouracil market include Pfizer, Merck, Bristol-Myers Squibb, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less   Read more